Acyclic Carbon To Carbon Unsaturation Patents (Class 514/720)
-
Publication number: 20090076114Abstract: The present invention relates to cis-1,2-substituted stilbene derivatives, or their pharmaceutically acceptable salts, glucosides or solvates, a pharmaceutical composition comprising the compound, and use of said compound for preparation of a drug for treatment and/or prevention of diabetes or improvement of diabetic complications.Type: ApplicationFiled: July 20, 2005Publication date: March 19, 2009Inventors: Zhiyun Kang, Zuze Wu, Zhuangrong Sun, Zhongxiong Tang
-
Publication number: 20090030069Abstract: An insect repellent composition that includes a blend of either all natural oils or synthetic ingredients, a sunscreen vitamin F, volatile silicones to extend the effective repellent life of the spray and a film forming polymer to resist water wash off. The natural oils and extracts can include citronella and orange and the synthetics can include D-limonene and phtalic acid.Type: ApplicationFiled: January 17, 2008Publication date: January 29, 2009Inventor: Stephen C. Perry
-
Publication number: 20090004104Abstract: Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.Type: ApplicationFiled: December 20, 2006Publication date: January 1, 2009Inventor: Ashutosh Chilkoti
-
Publication number: 20080312239Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.Type: ApplicationFiled: June 13, 2008Publication date: December 18, 2008Applicant: QUATRX PHARMACEUTICALS COMPANYInventors: Robert L. Zerbe, Alexander Bridges, Risto Lammintausta, Rochelle Hanley, Stuart Dombey
-
Publication number: 20080312337Abstract: Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis.Type: ApplicationFiled: August 19, 2008Publication date: December 18, 2008Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Byoung-Mog KWON, Kwang-Hee SON, Dong-Cho HAN, Su-Kyung LEE, Jung-Min KIM, Young-Hee KHO, Hyo-Kon CHUN, Jae-Young YANG
-
Publication number: 20080286209Abstract: Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure, tachycardia), hallucinations, alcohol withdrawal seizures, delirium tremens (DT), and memory loss); or for treating in treating convulsive seizure (e.g., epileptic seizure, etc.).Type: ApplicationFiled: February 6, 2006Publication date: November 20, 2008Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Jean-Baptiste Roullet, John C. Crabbe, JR., Pamela Metten
-
Patent number: 7449495Abstract: Described and claimed are compounds of Formula (I) in which R, R?, R?, A, and D have the meanings described in the text, as useful agents in the cure of pathologies characterized by altered angiogenesis and as antitumorals.Type: GrantFiled: June 20, 2007Date of Patent: November 11, 2008Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Sabrina Dallavalle, Lucio Merlini, Claudio Pisano, Loredana Vesci, Giuseppe Giannini, Sergio Penco
-
Publication number: 20080261982Abstract: Stilbene derivatives exhibit killing and suppression of growth activity against a variety of cancer cells, and are effective at suppressing tumor growth in vivo. The stilbene derivatives may be used in the treatment of diseases characterized by cell hyperproliferation including human malignancies and non-malignant diseases such as liver cirrhosis. Stilbenes may also disrupt abnormal vessels in tumor to achieve vascular disrupting effect to suppress tumor growth. Water soluble pro-drug forms of stilbene derivatives are particularly useful in suppressing tumor growth in vivo.Type: ApplicationFiled: April 23, 2007Publication date: October 23, 2008Inventors: Ruey-min Lee, Daniele Simoni
-
Publication number: 20080255078Abstract: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.Type: ApplicationFiled: November 22, 2006Publication date: October 16, 2008Inventor: Subba Reddy Katamreddy
-
Publication number: 20080234199Abstract: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.Type: ApplicationFiled: November 22, 2006Publication date: September 25, 2008Inventor: Subba Reddy Katamreddy
-
Publication number: 20080214509Abstract: This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject a Chemokine Receptor Antagonist (e.g., a CXCR4 antagonist) or Chemokine Antagonist (e.g., a SDF-1 antagonist) sequentially or simultaneously in combination with said Vascular Disrupting Agent.Type: ApplicationFiled: March 3, 2008Publication date: September 4, 2008Inventors: Robert Kerbel, Yuval Shaked
-
Publication number: 20080188557Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, acne, alopecia, hirsutism, a wound, prostate cancer, bladder cancer, liver cancer, breast cancer and Kennedy's disease.Type: ApplicationFiled: January 8, 2008Publication date: August 7, 2008Inventors: Charles C.Y. Shih, Qian Shi, Hui-Kang Wang, Ching-Yuan Su
-
Patent number: 7358236Abstract: The present invention provides a method of using anti-hypertensive agents (“AHAs”) to attenuate the transient increase in blood pressure observed in patients where Vascular Targeting Agents (“VTAs”) are administered to treat diseases associated with malignant neovascularization. The invention also relates to pharmaceutical compositions comprising AHAs and VTAs, and to kits thereof.Type: GrantFiled: June 23, 2003Date of Patent: April 15, 2008Assignee: OXiGENE, Inc.Inventors: David Chaplin, Scott Young
-
Patent number: 7351420Abstract: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils and/or their constituents, plant essential oils and/or their constituents in admixture with known active pesticidal compounds or plant essential oils and/or their constituents in admixture with other compounds not previously used as active ingredients in pesticidal formulations, such as, for example, so called signal transduction modulators. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally effective amount of the above synergistic and residual pesticidal compositions to a locus where pest control is desired.Type: GrantFiled: January 31, 2005Date of Patent: April 1, 2008Assignee: Ecosmart Technologies, Inc.Inventors: Steven M. Bessette, Myron A. Beigler
-
Patent number: 7291650Abstract: Pharmaceutical compositions containing plant essential oils, natural or synthetic, or mixtures or derivatives thereof, for the prevention and treatment of soft tissue cancer in mammals.Type: GrantFiled: January 20, 2004Date of Patent: November 6, 2007Assignee: Ecosmart Technologies, Inc.Inventors: Steven M. Bessette, Essam E. Enan
-
Publication number: 20070249647Abstract: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.Type: ApplicationFiled: April 25, 2007Publication date: October 25, 2007Inventors: David L. Vander Jagt, Lorraine M. Deck
-
Patent number: 7109245Abstract: Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising: wherein dashed lines independently represent either a single or a double bond, R1 is a lower alkyl, R2 is a lower alkyl, R3 is a lower alkyl or halogen, R4 is a lower alkyl or hydrogen, R5 is a lower alkyl or hydrogen, R6 is a hydrogen, lower alkyl or halogen, and R7 is a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.Type: GrantFiled: August 14, 2002Date of Patent: September 19, 2006Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Organix Inc.Inventors: George Kunos, Raj K. Razdan
-
Patent number: 7056862Abstract: The invention provides an agricultural chemical enhancer and an agricultural chemical composition which are safely used for crops without any phytotoxicity, have a potency enhancing action on various agricultural chemicals and promote the growth of a plant body to be intended to be grown. The invention relates to an agricultural chemical enhancer comprising at least one type selected from a specific alcohol compound, an ether compound and an ester compound.Type: GrantFiled: December 19, 2001Date of Patent: June 6, 2006Assignee: Kao CorporationInventors: Toshio Hayashi, Tadayuki Suzuki, Kazuhiko Kurita
-
Patent number: 6986898Abstract: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective amount of the above synergistic and residual pesticidal compositions to a locus where pest control is desired.Type: GrantFiled: June 28, 1999Date of Patent: January 17, 2006Assignee: Ecosmart Technologies, Inc.Inventor: Steven M. Bessette
-
Patent number: 6933320Abstract: An antitumor combination comprising a stilbene derivative and an anticancer compound selected from the group consisting of taxanes, alkylating agents, antimetabolites, vinca alkaloids, platinum compounds, epidophylloptoxins, and antibiotics as the active ingredients is provided. Methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like are also provided.Type: GrantFiled: March 15, 2002Date of Patent: August 23, 2005Assignee: Aventis Pharma S. A.Inventor: Marie-Christine Bissery
-
Patent number: 6875775Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2, which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C?CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and ?R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.Type: GrantFiled: April 8, 2003Date of Patent: April 5, 2005Assignee: Hormos Medical Oy LTDInventors: Marja-Liisa Södervall, Arja Kalapudas, Lauri Kangas, Risto Lammintausta, Pirkko Härkönen, Kalervo Väänänen, Arto Karjalainen
-
Patent number: 6855341Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.Type: GrantFiled: November 4, 2002Date of Patent: February 15, 2005Inventor: Jeffrey B. Smith
-
Patent number: 6841577Abstract: A pesticide for cockroaches and larvae which is based on purified naturally occurring plant substances. Phenethyl propionate; methyl salicylate; pulegone; carvacrol; thymol; thyme oil; citronellal; a three-blend of eugenol, ?-terpineol and cinnamic alcohol; a four-blend of benzyl alcohol, phenethyl alcohol, phenethyl propionate and ?-terpineol; and a five-blend of thymol, t-anethole, ?-terpineol, eugenol and citronellal have been used as the pesticide. The pesticide affects the octopamine receptor site in the cockroach. The five-blend has been used as a pesticide for Asian armyworms and green peach aphid nymphs. Methods of use of the pesticides are disclosed.Type: GrantFiled: December 18, 2001Date of Patent: January 11, 2005Assignee: Ecosmart Technologies, Inc.Inventors: Steven M. Bessette, Myron A. Beigler
-
Patent number: 6835754Abstract: 3,4,5-trisubstituted aryl nitrone compounds having the formula: where R1-R4 are as defined in the specification are useful as therapeutics for neuropathic pain conditions in mammals.Type: GrantFiled: January 8, 2002Date of Patent: December 28, 2004Assignee: Renovis, Inc.Inventors: L. David Waterbury, Paul L. Wood, M. Amin Khan, Ravindra B. Upasani
-
Publication number: 20040248992Abstract: The present invention has for its object to provide a method and a composition for achieving a more efficient recovery of the antioxidant activity of plasma LDL, or even augmentation thereof, which has been depressed by the use of an antihyperlipidemic or cholesterol-lowering drug to thereby insure a potentiated antiarteriosclerotic efficacy.Type: ApplicationFiled: July 16, 2004Publication date: December 9, 2004Applicant: KANEKA CORPORATIONInventors: Kenji Fujii, Taizo Kawabe, Kazunori Hosoe, Takayoshi Hidaka
-
Publication number: 20040242696Abstract: Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.Type: ApplicationFiled: March 1, 2004Publication date: December 2, 2004Inventors: David J. Chaplin, Klaus Edvardsen, Kevin G. Pinney, Joseph Anthony Prezioso, Mark Wood
-
Publication number: 20040229960Abstract: The present invention is directed to the administration of vascular targeting agents, particularly a tubulin binding agent, for the treatment of ocular neovascularization, ocular tumors, and conditions such as diabetic retinopathy, retinopathy of prematurity, retinoblastoma and macular degeneration.Type: ApplicationFiled: December 9, 2003Publication date: November 18, 2004Inventors: David Sherris, Mark Wood
-
Patent number: 6812258Abstract: Pharmaceutical compositions containing plant essential oils, natural or synthetic, or mixtures or derivatives thereof, for the prevention and treatment of soft tissue cancer in mammals.Type: GrantFiled: July 9, 2002Date of Patent: November 2, 2004Assignee: Ecosmart Technologies, Inc.Inventors: Steven M. Bessette, Essam E. Enan
-
Publication number: 20040192621Abstract: The present invention relates to an anti-tumor agent containing a tubulin polymerization-inhibitory active substance and an anti-inflammatory active substance. The present invention also relates to an anti-tumor pharmaceutical preparation containing one or more tubulin polymerization-inhibitory active substance and/or anti-inflammatory active substance, which can be individually combined with one or more additional tubulin polymerization-inhibitory active substance and/or anti-inflammatory active substance. The present invention also relates to methods and therapeutic regimens for administering the same to a subject in need thereof.Type: ApplicationFiled: December 24, 2003Publication date: September 30, 2004Applicant: AJINOMOTO CO., INCInventors: Yukio Nihei, Yoshihiro Morinaga, Manabu Suzuki, Yasuyo Suga
-
Patent number: 6790868Abstract: Antimicrobial compounds, compositions containing the same, and methods of using of the same for reducing the presence of microorganisms on a substrate or in a fluid environment comprising an antimicrobial effective carrier and at least one antimicrobial compounds including non-halogenated phenoxy and/or benzyloxy substituted phenol compounds.Type: GrantFiled: December 20, 2001Date of Patent: September 14, 2004Assignee: Warner-Lambert CompanyInventors: David Scott Harper, Robert A. Coburn, Constantine Georgiades, Andre Soshinsky, Marianne D. Huntley
-
Patent number: 6773702Abstract: A method of treating immune suppression in a warm-blooded animal bearing a tumor, by administering to the animal an amount of combretastatin A4 and/or a prodrug thereof effective to enhance immune responsiveness without causing vascular destruction. Immunotherapy treatment to inhibit or kill tumor cells includes administering to the animal an immune-response-stimulating agent such as a vaccine of tumor cells genetically modified to produce an immune-response-enhancing cytokine while counteracting tumor-induced immune suppression in the animal by administering combretastatin A4 and/or a prodrug thereof.Type: GrantFiled: December 26, 2001Date of Patent: August 10, 2004Assignees: OXiGENE, Inc., Bristol-Myers Squibb CompanyInventors: Ronald W. Pero, Francis Y. F. Lee, Klaus Edvardsen, Hans Olov Sjögren
-
Patent number: 6774123Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.Type: GrantFiled: July 28, 1999Date of Patent: August 10, 2004Assignee: V.I. Technologies, Inc.Inventors: Edward I. Budowsky, Samuel K. Ackerman, Andrei A. Purmal, Clark M. Edson, Martin D. Williams
-
Publication number: 20040143023Abstract: The present invention relates materials and methods for synthesizing stilbenes, and in particular to processes for the synthesis of substituted stilbenes such as combretastatin A4. The present invention relates in particular to methods which are stereoselective for either the cis or the trans isomer of the substituted stilbene, using a Perkin-type condensation of an arylacetic acid and a substituted benzaldehyde, followed by a decarboxylation reaction to produce the substituted cis-stilbenes or a Suzuki-type reaction involving a Z or E-ethenyl halide and a substituted boronic acid in the presence of a palladium catalyst to produce specifically either the Z or E-isomer of substituted stilbenes.Type: ApplicationFiled: March 3, 2004Publication date: July 22, 2004Inventors: John Anthony Hadfield, Alan Thomson McGown, Keira Gaukroger, Lucy Annette Hepworth, Nicolas James Lawrence
-
Patent number: 6740338Abstract: The present invention relates to a reduced form of Coenzyme Q also known as ubiquinol in oral dosage form such as a gelatin capsule, preferably a soft gelatin capsule. Compositions according to the present invention include storage stable compositions comprising effective amounts of ubiquinol in combination with an amount of a reducing agent effective to maintain ubiquinol in its reduced state when formulated in capsules, tablets and other orally administrable form. Methods of use are also disclosed.Type: GrantFiled: January 20, 2000Date of Patent: May 25, 2004Inventor: Raj K. Chopra
-
Patent number: 6723738Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2 , which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C≡CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.Type: GrantFiled: April 8, 2003Date of Patent: April 20, 2004Assignee: Hormos Medical Oy LtdInventors: Marja-Liisa Södervall, Arja Kalapudas, Lauri Kangas, Risto Lammintausta, Pirkko Härkönen, Kalervo Väänänen
-
Publication number: 20040067255Abstract: The present invention is directed to the use of vascular targeting agents or pharmaceutically acceptable salts thereof for administration in divided doses to a warm-blooded animal, such as a human. Also disclosed is a medicament comprising two or more fraction of doses of a vascular targeting agent, or a pharmaceutically acceptable salt thereof, which together add up to a total daily dose, or administration in divided doses for use in a method of treating a human or warm-blooded animal. A kit comprising two or more fractions of doses of a vascular targeting agent or a pharmaceutically acceptable salt thereof, which together add up to a total daily dose, for administration in divided doses is also disclosed.Type: ApplicationFiled: October 7, 2002Publication date: April 8, 2004Inventors: David J. Chaplin, Sally Hill
-
Patent number: 6696484Abstract: Pharmaceutical compositions and methods for treating androgen related disorders. The pharmaceutical compositions may include a 5&agr;-reductase inhibitor, such as natural and synthetic flavanoids, catechols, curcumin-related substances, quinones, catechins, particularly epigallocatechin derivatives, fatty acids, and the salts, esters, analogues, pro-drugs, isomers, racemic mixtures, or derivatives of any of the foregoing. The use of testosterone (or DHT) combinations with the aforementioned 5&agr;-reductase inhibitor compounds is also contemplated.Type: GrantFiled: April 24, 2002Date of Patent: February 24, 2004Assignee: University of Chicago Office of Technology and Intellectual PropertyInventors: Shutsung Liao, Richard Hiipakka
-
Patent number: 6689922Abstract: The invention concerns novel bi-aromatic compounds having the formula: which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.Type: GrantFiled: July 26, 2001Date of Patent: February 10, 2004Assignee: Galderma Research & Development S.N.C.Inventor: Jean-Michel Bernardon
-
Publication number: 20040018958Abstract: Compounds of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating epithelium regrowth, inhibiting cutaneous fibroblast proliferation, decreasing collagen deposit, suppressing fibrogenic growth factor and subsiding inflammatory cytokine, and are useful inhibiting the main features of radiation cutaneous syndrome. Results include a decrease in skin swelling, promotion of epithelium healing, and prevention of cutaneous fibrosis, ulceration and necrosis. The present invention provides methods of treating, preventing or ameliorating radiation-induced skin damage by administering a therapeutically effective amount of a histone deacetylase inhibitor.Type: ApplicationFiled: July 25, 2002Publication date: January 29, 2004Inventor: Yih-Lin Chung
-
Patent number: 6677383Abstract: The present invention concerns enzymatic aromatic hydroxylation-activated prodrugs, particularly anti-tumor prodrugs and those which are specifically activated by the hydroxylation activity of the enzyme CYP1B1.Type: GrantFiled: August 7, 2000Date of Patent: January 13, 2004Assignee: De Montfort UniversityInventors: Gerard Andrew Potter, Lawrence Hylton Patterson, Michael Danny Burke, Paul Crispin Butler
-
Publication number: 20030228269Abstract: The present invention relates to the use of resveratrol and its derivatives as active principles in antidandruff formulations.Type: ApplicationFiled: May 16, 2003Publication date: December 11, 2003Inventors: Mario DeRosa, Mose Rossi
-
Patent number: 6653327Abstract: The present invention is directed to a mixture of tetrahydrocurcuminoids which can be used for regulating random, intracellular protein cross-linking an optimizing cell electric potential in a patient.Type: GrantFiled: October 9, 2001Date of Patent: November 25, 2003Assignee: Sabinsa CorporationInventors: Muhammed Majeed, Vladimir Badmaev
-
Publication number: 20030181531Abstract: The present invention is directed to the administration of vascular targeting agents, particularly a tubulin binding agent, for the treatment of ocular neovascularization, ocular tumors, and conditions such as diabetic retinopathy, retinopathy of prematurity, retinoblastoma and macular degeneration.Type: ApplicationFiled: February 11, 2003Publication date: September 25, 2003Inventors: David Sherris, Mark Wood
-
Patent number: 6624197Abstract: Novel diphenylethylene and styrenes are provided which are administered orally to decrease blood glucose levels in rats. The glucose tolerance in insulin resistant rats is also shown, as well as lowering of triglyceride levels in serum insulin resistant, hyperinsulinemic and hypertriglycedemic rats. The compounds are orally effective anti-diabetic agents that potentially may reduce abnormality of glucose and lipid metabolism in diabetes.Type: GrantFiled: August 17, 2000Date of Patent: September 23, 2003Assignee: Calyx Therapeutics, Inc.Inventors: Bishwajit Nag, Satyanarayana Medicherla, Debendranath Dey
-
Publication number: 20030171441Abstract: The invention relates to the field of antiviral agents, and more specifically to antiviral therapy.Type: ApplicationFiled: March 14, 2002Publication date: September 11, 2003Inventor: Johannes Servatius Leonardus Maria Nottet
-
Publication number: 20030157204Abstract: Novel compositions of matter containing aromatic compounds and terpenoids which are present in and may preferably be derived from the plant Alpinia galanga (Zingiberaceae) show synergistic effects with respect to immunomodulation, and they significantly suppress hypersensitivity reactions. Thus they are used for preparing medicaments for these purposes and, more specifically, for the treatment or prevention of IgE mediated allergic reactions and conditions, such as asthma, allergic rhinitis, atopic eczema or anaphylaxis, and autoimmune disorders, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis or psoriasis, as well as for the alleviation of pain. They can for example be formulated into pharmaceuticals, cosmetics or dietary supplements. A method of preparing such compositions from Alpinia galanga is also described.Type: ApplicationFiled: January 2, 2003Publication date: August 21, 2003Applicant: Enrovita A/SInventors: Morten Sloth Weidner, Morten Just Petersen, Nina Worm Jensen
-
Publication number: 20030124101Abstract: This invention provides methods for treating and for inhibiting the onset of cancer in a subject comprising administering an agent that inhibits the ability of Sir2&agr; to inhibit p53-dependent apoptosis. This invention also provides a related method for inducing the death of a cell. This invention further provides a method for decreasing the amount of damage to a subject's cells caused by physical stress comprising administering agent that increases the amount of Sir2&agr; in the subject's cells and/or the ability of Sir2&agr; to inhibit p53-dependent apoptosis in the subject's cells. This invention further provides related methods for prolonging the life-span of a subject, decreasing the amount of damage to a cell caused by physical stress, and prolonging the life-span of a cell. Finally, this invention provides two articles of manufacture for performing the instant methods.Type: ApplicationFiled: June 14, 2002Publication date: July 3, 2003Inventors: Wei Gu, Jian Yuan Luo
-
Publication number: 20030118617Abstract: A method for treating the skin of a human is disclosed.Type: ApplicationFiled: December 21, 2001Publication date: June 26, 2003Applicant: AVON PRODUCTS, INC.Inventors: Lynn Soby, Eugenia H. Theophilus, Dmitri Ptchelintsev, Paul S. Attar
-
Patent number: 6576645Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2, which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C≡CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.Type: GrantFiled: November 15, 2000Date of Patent: June 10, 2003Assignee: Hormos Medical Oy LtdInventors: Marja-Liisa Södervall, Arja Kalapudas, Lauri Kangas, Risto Lammintausta, Pirkko Härkönen, Kalervo V{umlaut over (aa)}nänen
-
Patent number: 6576660Abstract: Compounds that inhibit 5-alpha-reductase are provided. The compounds are used to treat prostate cancer, breast cancer, obesity, skin disorders and baldness.Type: GrantFiled: April 28, 2000Date of Patent: June 10, 2003Assignee: Arch Development CorporationInventors: Shutsung Liao, Richard A. Hiipakka